GenWay Biotech reports that it has become CLIA certified and received a California lab license. The company is seeking to obtain CAP (College of American Pathologists) accreditation by the end of the year. Furthermore, GenWay’s lab is under construction for the addition of a Class 10,000 clean room, which should be complete in August.
GenWay, which has traditionally supplied antibodies and antigens for the development of diagnostic kits, will now be able to test immunological biomarkers for the develop diagnostic tests. The company says that in the coming weeks it will add cancer biomarker tests to its portfolio as well as tests for infectious diseases such as sexual transmitted diseases.
GenWay’s platform focuses on producing avian IgY antibodies from proteins of human, animal, plant, bacterial, and other sources. The company also offers single chain recombinant scFv and shark vNAR antibody technologies.